<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined possible anticancer effects of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) in 6074 Chinese with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> free of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at enrolment </plain></SENT>
<SENT sid="1" pm="."><plain>During a median follow-up of 4.93 years, 270 patients developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Use of TZDs was associated with reduced risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in a dose-response manner in multivariable analysis </plain></SENT>
</text></document>